Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Share-based Compensation (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Share-based Compensation for 6 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 11.93% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, down 62.44% year-over-year, with the annual reading at $2.8 million for FY2025, 62.44% down from the prior year.
  • Share-based Compensation hit $1.0 million in Q4 2025 for Bolt Biotherapeutics, up from $407000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.9 million in Q1 2022 to a low of $407000.0 in Q3 2025.
  • Historically, Share-based Compensation has averaged $1.9 million across 5 years, with a median of $2.1 million in 2021.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 837.33% in 2021 and later crashed 77.88% in 2025.
  • Year by year, Share-based Compensation stood at $2.1 million in 2021, then decreased by 0.89% to $2.1 million in 2022, then dropped by 2.59% to $2.1 million in 2023, then crashed by 42.84% to $1.2 million in 2024, then decreased by 11.93% to $1.0 million in 2025.
  • Business Quant data shows Share-based Compensation for BOLT at $1.0 million in Q4 2025, $407000.0 in Q3 2025, and $625000.0 in Q2 2025.